Status:
UNKNOWN
PET Changes in Alzheimer's Disease (AD)
Lead Sponsor:
National Institute on Aging (NIA)
Conditions:
Alzheimer Disease
Eligibility:
All Genders
20-90 years
Brief Summary
The purpose of this study is to identify the earliest predictors of memory and brain deterioration in pre-clinical Alzheimer's disease using positron emission tomography (PET) to monitor brain glucose...
Detailed Description
Previous studies indicate that the brain's glucose metabolism rate potentially may be an early indicator of damage to particular regions of the brain caused by AD, including loss of neurons, synapses,...
Eligibility Criteria
Inclusion
- Males and females with a minimum high school education and between the ages of 50 and 90 will be selected for Groups 1 and 2. For Group 3, normal subjects between the ages of 20 and 49 years of age will be selected. The Groups 1 and 2 will be balanced for age, and all three groups balanced for gender and ApoE genotype.
- Discontinuance of all psychotropic and/or cognitively active medication at least four weeks prior to evaluation.
Exclusion
- Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, lacunar infarcts, seizures, mental retardation or serious neurological disorder.
- Significant history of alcoholism or drug abuse.
- Any history of psychiatric illness (e.g., schizophrenia, mania or depression).
- Any focal signs or significant neuropathology.
- A score of 4 or greater on the Modified Hachinski Ischemia Scale, indicative of cerebrovascular disease.
- A total score of 16 or more on the Hamilton Depression Scale to exclude possible cases of primary depression.
- Evidence of clinically relevant hypertensive, cardiac, pulmonary, vascular, metabolic or hematologic conditions. Specific exclusion will be made for individuals with fasting glucose levels \>110 mg/dl.
- Physical impairment of such severity as to adversely affect the validity of psychological testing.
- Hostility or refusal to cooperate.
- Any prosthetic devices (e.g., pacemaker or surgical clips) that could be affected by the magnetic field employed during MRI imaging.
- Evidence of cognitive or memory impairment reaching early AD levels at the initial evaluation. At baseline, delayed paragraph recall z-scores \> 2 below the reference group.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2005
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00094913
Start Date
May 1 2004
End Date
April 1 2005
Last Update
May 27 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Brain Health, Silberstein Institute, New York University
New York, New York, United States, 10016